Software Engineer

ASCO Guidelines coming to DoxGPT. Clinical oncology is defined by continual discovery. New trials, biomarkers, and therapeutic advances continue to reshape best practices, making timely access to the latest evidence essential. Today, Doximity, Inc. is thrilled to announce a new agreement with the American Society of Clinical Oncology (ASCO(R) that will bring ASCO Guidelines into DoxGPT, Doximity's evidence-backed, HIPAA-compliant medical AI for clinicians. DoxGPT, powered by PeerCheck(TM), combines AI automation with physician verification, reinforcing the foundational role that peer review and expert consensus play in evidence-based medicine. ASCO Guidelines include evidence-based recommendations and outline appropriate methods of treatment and care for clinicians. ASCO is a leading professional organization for physicians and oncology professionals caring for people with cancer. Its guidelines offer timely, trustworthy information to help clinicians make evidence-based decisions. ASCO Guidelines include both standard and "living guidelines," which are specifically designed for areas of oncology where evidence is evolving rapidly. Standing expert panels conduct systematic reviews of health literature and update living guidelines on a regular schedule. Bringing ASCO's comprehensive guidelines into DoxGPT is part of Doximity's broader strategy to deliver clinical AI that physicians can trust. AI technology is quickly becoming a commodity, but medical trust is not. Clinicians want answers that are AI-fast and textbook-trusted. With the introduction of ASCO Guidelines, DoxGPT users can access current oncology standards with accuracy and confidence, as every ASCO guideline is reviewed by a multidisciplinary expert panel.

Doximity ranked #1 Best in KLAS Telehealth Video platform for fifth consecutive year. SAN FRANCISCO - (BUSINESS WIRE) - Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report. This is the fifth consecutive year that Doximity has earned the top spot, underscoring its position as a trusted, long-term partner for physicians and health systems. In addition to securing the #1 spot, Doximity received A-level ratings in all categories, including A+ ratings for culture, loyalty and value. These results are based on live interviews with health system leaders and their staff, reflecting high satisfaction with Dialer's reliability, ease of use, and real-world clinical impact. "Physicians continue to choose Dialer because it just works," said Jeff Tangney, co-founder and CEO of Doximity. "Our goal has always been to help physicians deliver high-quality care from wherever they are, and this recognition from KLAS validates that focus." Engagement with Dialer continues to reach new highs. Last quarter (October-December), clinicians used Dialer to complete more than 300,000 calls each workday. During last week's winter storms, a record number of clinicians used Dialer to complete more than 720,000 HIPAA-compliant calls and texts in a single day. Doximity Dialer is a HIPAA-compliant telehealth solution that enables clinicians to connect with patients by phone, video, and text while keeping their personal phone numbers private. The solution offers one-click voice and video visits, custom Caller ID, device and language optimization, and seamless transitions between voice and video, making it easy for clinicians to deliver care from anywhere. "The Best in KLAS awards recognize the vendors who consistently deliver excellence through partnership with healthcare organizations," said Adam Gale, KLAS CEO. "Winning this award means customers trust you to help them succeed in our rapidly changing healthcare landscape. This means helping them to improve patient care, achieve better outcomes, and find true ROI. We're honored to amplify the voice of providers and payers at KLAS, and to celebrate those vendors who turn feedback into action." About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. About KLAS Research KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.

Doximity, the digital platform for US medical professionals, reported revenue of $185.1 million for its fiscal third quarter ended 31 December 2025, up 10% year-over-year. The company reported net income of $61.6 million and adjusted EBITDA of $111.4 million, representing a 60.2% margin. The platform now has over one million quarterly active prescribers on its newsfeed, 720,000 using workflow products, and over 300,000 engaging with AI features. CEO Jeff Tangney said AI integration has enhanced the platform's utility. For the fiscal fourth quarter ending 31 March 2026, Doximity expects revenue between $143 million and $144 million. The company's board authorised a new $500 million share repurchase programme with no expiration date.